On April 30th, Bristol Myers Squibb announced that it was the world's first myocardial myosin inhibitor, Mefantuo& Reg; (Common name: Mavakaitai Capsules) has been given priority review and approval by the National Medical Products Administration of China for the treatment of adult patients with obstructive hypertrophic cardiomyopathy (HCM) in the New York Heart Association (NYHA) heart function classification II-III, in order to improve exercise ability and symptoms.